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INTRODUCTION  AND  IMPORTANCE:  The  initial  misdiagnosis  and  delayed  treatment  for inflammatory
breast  cancer  in men  is brought  about  by  its rarity  and  lack  of readily  available  guidelines  on pathways.
CASE  PRESENTATION:  A  78-year-old  male  presented  to  the  breast  clinic  with  an  abscess  and  was  later
diagnosed  with  inflammatory  breast  cancer.  He  presented  with  an abscess  and  was  initially  treated  with
antibiotics.  Imaging  showed  a large  left breast  mass  consistent  with  inflammatory  carcinoma  with  axillary
lymph  node  involvement.  Patient  was  started  on  Tamoxifen  as  a bridge  for surgery  with  no  response.
He  eventually  had  a mastectomy  and  axillary  clearance  with  the histology  confirming  the  diagnosis
and  tumour  emboli  in the  lymphatic  vessels.  Chemotherapy,  radiation  and  dual  hormone  therapy  were
included  in  the adjuvant  treatment  plan.  Two  episodes  of neutropenic  sepsis  led  to  completing  only  five
out  of six planned  chemotherapy  cycles.
CLINICAL  DISCUSSION:  A review  of  literature  and  the  reported  cases  was  done  by  the  team  to contribute
to  the  little  information  published  about  the disease  and  its  management.  The  presented  to  the  breast
clinic  during  the  height  of  the  SARS-  CoV-2  pandemic.  The  global  impact  of  SARS-CoV-19  made  surgical
teams  find  ways  to lessen  elective  lists  to  give  way  for patients  affected  during  the pandemic.

















can  be  missed  leading  to  
©  2021  Published  by  
under  t
1. Introduction and importance
Breast cancer in men  is a rare disease worldwide [1]. Because
of this, most treatment pathways are based on results of trials on
women with the diagnosis. This is further supported by the fifth
version of the National Comprehensive Cancer Network Guidelines
released in 2020 stating that the management of breast cancer in
men  and women is similar overall with special considerations per-
tinent to male patients [3]. Unusual presentations, more specifically
breast cancer that is inflammatory in nature, poses challenges on
its management. Inflammatory breast cancer is commonly asso-
ciated with bad prognosis [2]. Reducing delays in diagnosis by
early recognition of the disease is key. The limited data on male
inflammatory breast cancer that is currently published serves only
as a guide, highlighting the subtle similarities and major differ-
ences in the presentation and treatment of male inflammatory
breast cancer. Interestingly, the manifestation of the condition pre-
sented in the cases currently published has not shown a definitive
pattern of disease progression. This case report discusses a male
patient diagnosed with inflammatory breast cancer, further sup-
∗ Corresponding author at: Norfolk and Norwich University Hospital, Colney Lane,
Norwich NR4 7UY, UK.
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orted by a literature review. The patient has given the authors
he consent to discuss the case in this article, along with photos
rovided by the patient and those taken in the clinical setting.
his case report followed the guidelines set by the SCARE criteria
18].
. Case presentation
A 78-year-old man  was referred to the one-stop breast clinic
ith a red, tender and hot swelling lump on his left breast with
us discharge (Fig. 1a). The condition has developed over a month
efore and was treated in the primary care with no improvement.
e was given a two-week course of Flucloxacillin 500 mg  TDS. That
reatment resulted in the development of a sinus discharging pus
ith a residual abscess underneath. He has a history of bilateral
imple gynecomastia diagnosed following a previous referral to
he breast clinic three years ago. He is not diabetic, doesn’t smoke
nd has no family history of breast cancer. His past medical history
ncludes Hypertension, Atrial Fibrillation, Diabetes and Hyperlip-
daemia. His regular medications include Allopurinol, Amlodipine
nd Warfarin.When he was examined, the large bilateral gynecomastia was
oted, and an abscess/inflammatory mass was  present on the left
ide. At that stage, the clinician organised an ultrasound scan as
 mammogram was  not possible due to severe pain. Ultrasound
s an open access article under the CC BY-NC-ND license (http://creativecommons.
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Fig. 1. Photos showing disease progression (all provided by the patient for use in literature and education): (a) Taken in March 2020. (b) Taken in June 2020, about three

















Fig. 2. (a) Ultrasound at original presentation showing an excess of 50 mm abscess 
was  recommended. (b) Medio-Lateral Oblique mammographic view showing a we
appearances are consistent with an inflammatory left breast carcinoma.
scan showed a large abscess in the left retroareolar region (Fig. 2a).
Aspiration was attempted but did not yield any fluid. He was given
the advice to continue the same antibiotic treatment and another
appointment was arranged for clinical reassessment of improve-
ment of the abscess. At that point, a mammogram was performed
showing shows a well-marginated, round 60 mm mass with overly-
ing skin thickening on the left breast (Fig. 2b). The right side showed
simple gynecomastia.
The repeat ultrasound showed an irregular vascularised hypoe-
choic mass measuring up to 55 mm seen to directly invade the
thickened overlying skin in the area of the central left breast. Ultra-
sound to the left axilla further showed at least four enlarged and
morphologically abnormal lymph nodes. Radiologic studies report
that the appearances are consistent with an inflammatory left
breast carcinoma and metastatic axillary lymph nodes.
To complete the triple assessment, a core biopsy was  done for
the left breast and the axillary lymph node.
The biopsy from the breast and the node showed a grade 2 Inva-
sive ductal carcinoma, oestrogen receptor positive. The case was






 left retroareolar region that failed to yield any aspirate fluid. Clinical management
ginated round 60 mm mass with overlying skin thickening on the left breast. The
f the first wave of the Covid-19 pandemic. Due to that situation,
he MDT  recommended primary bridging hormone treatment, and
he patient was started on Tamoxifen 20 mg tablets. This was  con-
idering the advanced nature of the disease and the diagnosis of
nflammatory breast cancer. Staging investigations were organised
nd revealed no distant metastasis.
The plan was  to downstage the tumour with the primary hor-
one treatment in anticipation of surgery. Three months later, the
atient was  seen in the clinic for reassessment following hormone
reatment. There was  no real response with Tamoxifen. This led
o the patient being listed for mastectomy and axillary clearance
Fig. 3).
During the surgery performed by the patient’s consultant breast
urgeon, chest wall involvement was found at the lateral area of
he breast. This suggests how aggressive the tumour was  as the
ttachment to the muscle was  not visible in previous imaging. Final
urgical histology revealed no cellular response (Miller and Payne
rade 1) to Tamoxifen. The tumour size has increased from 60 mm
n initial imaging to 90 mm.  Muscle involvement was confirmed
nd 4 out of the 22 harvested lymph nodes contained metastases.
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Fig. 3. Photos taken on the day of su
The presence of tumour emboli was confirmed in 1–2 dermal lym-
phatic vessels.
At the post-operative MDT, the question of further systemic
treatment was discussed. It was clear that the tumour unusu-
ally didn’t show any response to Tamoxifen. Therefore, a GnRH
(Gonadotropin Releasing Hormone) analogue plus an aromatase
inhibitor was recommended for adjuvant endocrine treatment
as per the National Comprehensive Cancer Network Guidelines
[3]. Post-mastectomy radiotherapy was recommended due to the
involvement of the deep margin and axillary lymph nodes.
The MDT  also recommended to discuss chemotherapy. This
decision would have to be balanced against the medical comor-
bidities of the patient versus the definite benefit of chemotherapy
in his case.The suggestion, rationale and plans for chemotherapy were
explained to the patient by the oncology team. The Fluo-
rouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-T)






Inflammatory Breast Cancer in male.
Case No Author Age
(Years)
Clinical Presentation Nodal Dis
presentat
1 Treves [11] 66 Painless mass of the axilla Axillary 
2  Treves [11] 72 Erythema and swelling of
bilateral anterior chest wall
Neck, sup
and bilate
3  Treves [11] 70 Erythema of left breast Axillary 
4  Sina and Samorodin [12] 72 Erythema of bilateral
anterior chest wall
Axillary 
5  Yamamoto et al. [13] 68 Erythema and swelling of
left anterior chest wall
Axillary 
6  Spigel et al. [14] 48 Erythema and thickening
of right breast
None 
7  Skarin [15] 69 Diffuse rash of left anterior
chest wall/severe back pain
None 
8  Choueiri et al. [16] 56 Neck swelling/ warmth of
the right anterior chest
wall/gynecomastia
None 
9  Morita et al. [6] 72 Erythema of the right chest
wall/right breast mass
Axillary 
10  Hyakudomi et al. [5] 85 Erythema and induration
of the right chest wall
Axillary 
11  Loewen et al. [4] 51 Erythema and peau ‘d
orange of right breast
Axillary a
cervical c
12  Tashima et al. [17] 67 Multiple small masses of
the left anterior chest wall
– 
13  Current 78 Tender hot swelling of left
breast with pus discharge
Axillary 
3
 five months since day of diagnosis.
iscussed with the patient and he accepted the recommenda-
ions.
At the end of the fifth cycle, the team met  with the patient
o discuss omitting the final cycle as the patient suffered neu-
ropenic sepsis twice. Moving forward, the patient was  satisfied
ith the plan and agreed to proceed with Radiotherapy and dual
nti-hormone treatment.
. Literature review
Little is known about Inflammatory Breast Cancer (IBC) in men
ence, diagnosis may  be missed and often delayed. As in the case of
emales, IBC diagnosis is largely a clinical diagnosis. This accounts
or the possible delay in diagnosis of this condition. Treatment for
BC in men  is commonly taken after therapeutic responses seen in
emales diagnosed with the disease [4]. Table 1 shows the sum-






None Not reported –
raclavicular
ral inguinal
None Not reported –
None Not reported –
None Not reported –
Pleura Not reported Systemic chemotherapy
None Not reported Neoadjuvant
chemotherapy and
mastectomy
Bone Not reported Hormonal therapy
None ER (-), PR (-),
HER2/neu (-)
Systemic chemotherapy
None ER (-), PR (-) Mastectomy and adjuvant
chemotherapy with
radiation







ER (+), PR (+),
HER2/neu (-)
Hormone Therapy














































A. Tanhueco and M.M.G. Youssef 
accounting to 13 patients with an age range of 48–85 years old,
including the current patient.
Generally, 92 % of male breast cancers are ER positive [1]. Out of
the now 13 reported cases of inflammatory breast cancer in men,
six were tested for ER, PR and HER2 expression, two of which were
triple negative [1,5] and one tested for ER and PR only, turned out
receptor negative [6].
This patient, who is now the 13th reported case of inflammatory
breast cancer in men, is only the third hormone receptor positive
reported inflammatory breast cancer case in men. The first reported
ER positive patient was initially treated with Exemestane only, due
to lack of medical insurance and patient’s apprehensions. At the
12-month follow up, the patient has not reported any medication
intolerance and continued the treatment with Everolimus and radi-
ation therapy [4].
The details of the systemic treatment of eight out of the first
12 cases were described in the literature. Six out of eight of these
patients were given chemotherapy [5].
Of the previous cases collated, two had no data on Lymph node
involvement and only one had no actual lymph node involvement.
The rest, including the current case, had at least an axillary lymph
node metastasis [4]. Evidently, there is still marked delay in identi-
fying this aggressive disease causing a higher likelihood that it has
already reached the lymph nodes once the diagnosis is made.
4. Discussion
Inflammatory breast cancer is said to be a clinico-pathological
diagnosis [2]. What is generally agreed is its abrupt onset (no more
than 6 months) with erythema involving more than a third of the
breast [2]. Though pathognomonic and common in IBC, dermal lym-
phatic invasion was found out to be not required to establish a
diagnosis [2].
Generally, for breast cancer in men, Tamoxifen is commonly
used because of its efficacy in the both adjuvant and palliative set-
tings [7]. There is no available literature to support its use in the
neo-adjuvant setting and therefore the evidence is very limited.
Though Tamoxifen remains to be the first line hormone therapy
for male breast cancer [7], occasions where it is not an option for
treatment for men  who test positive for oestrogen receptors is not
unheard of. Deep vein thrombosis and weight gain are reported
toxicities warranting discontinuation of the treatment [1,7]. These
cause a large proportion of men  to stop treatment before 5 years
[1].
In men, single-agent adjuvant treatment with an aromatase
inhibitor has been associated with inferior outcomes compared to
Tamoxifen alone, likely due to inadequate estradiol suppression,
and is not recommended [3].
This course of treatment was displayed in a case reported by
Jiang et al. [8]. This was of a man  who was initially treated with
Letrozole as first line endocrine treatment. This was discontinued
after 7 months because of disease progression. This was followed
by Goserelin plus Anastrazole shortly after distant metastasis was
found. This treatment provided stability of the disease for a year
prior to progression. Examestane replaced Anastrazole for the next
11 months, again, providing stability before further progression [8].
The extent of muscle involvement that was seen during the
mastectomy of the patient indicated adjuvant radiotherapy. Men
are more likely to be offered post mastectomy chest wall radia-
tion therapy (PMRT) due to concern of adequate surgical margins
even in small tumours and the higher incidence of nipple or skin
involvement [1]. A radiotherapy boost may  be administered to his
chest wall to address this.
The risk of gynecomastia and breast cancer coexists in high
oestrogen states [9]. This association is bringing into question the
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he initially proposed idea that gynecomastia increases the risk for
reast cancer. The current patient still presents with gynecomastia
n the contralateral side.
The global event brought about by SARS-CoV-19 affected the
lective surgical activity immensely. More manpower support was
eeded for the critical care departments who care for patients with
he coronavirus disease 2019, hence a huge number of elective
urgeries were put on hold [10]. Surgical teams had to prioritise
lective lists and alter treatment paths for patients who do not
equire immediate surgery. It can be argued that the patient could
ave had chemotherapy as a neo adjuvant treatment. The situa-
ion in the healthcare system at the time of presentation required a
onscientious decision to attempt downstaging the tumour prior to
urgery. This led to the discovery of having no response to hormone
reatment, following discussion for more treatment.
. Conclusion
The limited data that we  currently have for male inflammatory
reast cancer still would not sufficiently provide a standard path-
ay for treatment.Men will still experience delay in diagnosis and
reatment due to the lack of published information and reliable
reatment pathways.
This reported case and literature review aim to add to the avail-
ble body of evidence available for the management of this rare
linical condition which can represent a challenge for clinicians
anaging breast cancer in men.
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